New York, Mar 23, 2015 - (ABN Newswire) - Regeneus Ltd (ASX:RGS) announced today that John Martin, CEO, will present at the 3rd Annual Regenerative Medicine Investor Day to be held Wednesday, March 25, 2015 in New York City.
Organised by the Alliance for Regenerative Medicine (ARM) and co-hosted with Piper Jaffray, a leading full-service investment bank and asset management firm serving clients in the U.S. and internationally this one-day investor meeting provides institutional, strategic and venture investors with unique insight into the financing opportunities for advanced therapies-based treatment and tools.
The program includes clinical and commercial experts who are on-hand to address specific questions regarding the outlook for these products, as well as offer insight into how advanced therapies could impact the standard of care in key therapeutic areas. In addition to presentations by more than 30 leading companies from across the globe, the event includes dynamic, interactive panels featuring research analysts covering the space, key clinical opinion leaders and top company CEOs. These discussions will explore themes specific to cell and gene therapy such as commercialisation, market access and pricing for breakthrough technologies, gene therapy delivery and upcoming milestones in the adoptive T-cell therapy space.
The following are specific details regarding Regeneus' presentation:
Event: ARM's Regen Med Investor Day
Date: March 25, 2015
Time: 4.50 - 5.05pm (EDT)
Location: Metropolitan Club, One East 60th Street, New York, NY 10022
A live-streaming webcast of all panels and company presentations will be available at: http://www.arminvestorday.com/webcast
and will be published on the event's website shortly after the conference. Attendance at this event is for credentialed investors and members of the media only. If you are interested in attending, please contact Laura Parsons at lparsons@alliancerm.org.
About: Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based ASX listed regenerative medicine company that develops and commercialises stem cell and other biological therapies for the human and veterinary health markets with a focus on musculoskeletal and oncology conditions. The company has a marketed autologous (patient's cells) product using adipose (fat) derived stem cells to treat human osteoarthritis (OA), HiQCell, which has been used to treat over 1000 arthritic joints. The company plans to commence a clinical trial of allogeneic (donor cells) adipose stem cells to treat human OA in Q2 2015.
Help employers find you! Check out all the jobs and post your resume.
Organised by the Alliance for Regenerative Medicine (ARM) and co-hosted with Piper Jaffray, a leading full-service investment bank and asset management firm serving clients in the U.S. and internationally this one-day investor meeting provides institutional, strategic and venture investors with unique insight into the financing opportunities for advanced therapies-based treatment and tools.
The program includes clinical and commercial experts who are on-hand to address specific questions regarding the outlook for these products, as well as offer insight into how advanced therapies could impact the standard of care in key therapeutic areas. In addition to presentations by more than 30 leading companies from across the globe, the event includes dynamic, interactive panels featuring research analysts covering the space, key clinical opinion leaders and top company CEOs. These discussions will explore themes specific to cell and gene therapy such as commercialisation, market access and pricing for breakthrough technologies, gene therapy delivery and upcoming milestones in the adoptive T-cell therapy space.
The following are specific details regarding Regeneus' presentation:
Event: ARM's Regen Med Investor Day
Date: March 25, 2015
Time: 4.50 - 5.05pm (EDT)
Location: Metropolitan Club, One East 60th Street, New York, NY 10022
A live-streaming webcast of all panels and company presentations will be available at: http://www.arminvestorday.com/webcast
and will be published on the event's website shortly after the conference. Attendance at this event is for credentialed investors and members of the media only. If you are interested in attending, please contact Laura Parsons at lparsons@alliancerm.org.
About: Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based ASX listed regenerative medicine company that develops and commercialises stem cell and other biological therapies for the human and veterinary health markets with a focus on musculoskeletal and oncology conditions. The company has a marketed autologous (patient's cells) product using adipose (fat) derived stem cells to treat human osteoarthritis (OA), HiQCell, which has been used to treat over 1000 arthritic joints. The company plans to commence a clinical trial of allogeneic (donor cells) adipose stem cells to treat human OA in Q2 2015.
Help employers find you! Check out all the jobs and post your resume.
